A Study to Assess the Burden of Herpes Zoster and Postherpetic Neuralgia in Japanese Adults Aged Sixty Years and Above

Conditions

Herpes Zoster

Keywords

Quality of life, Herpes zoster, Postherpetic neuralgia, Japan, Physician-practice, Adults, Health economics

Brief summary

The study aims to estimate the incidence of herpes zoster (HZ), proportion of postherpetic neuralgia (PHN) and the economic burden and impact on quality of life, in Japanese adults greater than or equal to sixty years of age.

Akiko Mizukami, Keiko Sato, Koichi Adachi, Sean Matthews, Katsiaryna Holl et al. (8 authors)

Clinical Drug Investigation2017-10-3064 citations

10.1007/s40261-017-0581-5

Economic Burden of Herpes Zoster and Post-Herpetic Neuralgia in Adults 60 Years of Age or Older: Results from a Prospective, Physician Practice-Based Cohort Study in Kushiro, Japan

Hiroyuki Nakamura, Akiko Mizukami, Koichi Adachi, Sean Matthews, Katsiaryna Holl et al. (14 authors)

Drugs - Real World Outcomes2017-10-0721 citations

10.1007/s40801-017-0119-4

Burden of herpes zoster and postherpetic neuralgia in Japanese adults 60 years of age or older: Results from an observational, prospective, physician practice‐based cohort study

Keiko Sato, Koichi Adachi, Hiroyuki Nakamura, Kazuhiro Asano, Akihiro Watanabe et al. (12 authors)

The Journal of Dermatology2016-12-0556 citations

10.1111/1346-8138.13639

Interventions

OTHERData collection

Case report forms (CRFs), logbooks and booklets.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

60 Years to No maximum

Healthy volunteers

No

Inclusion criteria

* Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol. * Written informed consent obtained from the subject. * A male or female greater than or equal to sixty years of age, presenting with HZ at the time of enrollment. * HZ diagnosis. * Is the subject's first outpatient diagnosis for this HZ episode. OR * Took place up to seven days prior to the initial visit for the present study. Note: Recurrent HZ cases may be enrolled as new cases based on the investigator's clinical practice.

Exclusion criteria

• Not applicable.

Design outcomes

Primary

Measure	Time frame
Total number of HZ cases reported in the study area, overall and within a specific age-group and gender. The following age-groups will be considered: 60-69, 70-79 and ≥ 80 years of age.	Approximately 1 year
Occurrence of HZ-associated PHN pain, persisting between 90 and 270 days after the initial visit for this study.	Day 90 - Day 270

Secondary

Measure	Time frame
Anamnestic information, clinical parameters and complications related to HZ.	Day 0 - Day 270
Direct medical, direct non-medical and indirect costs related to HZ.	Day 0 - Day 90
Quality of life (QoL) assessment in HZ subjects.	Day 0 - Day 90
Occurrence of HZ-associated hospitalisations.	Day 0 - Day 270
QoL assessment in PHN subjects.	Day 90 - Day 270
Impact of the following factors on the development of PHN: - age, - gender, - concomitant disease, - current immunosuppressive therapy, - HZ severity at first consultation, - timing of initiation of treatment with antiviral agent etc.	Day 0 - Day 270
Direct medical, direct non-medical and indirect costs related to PHN.	Day 90 - Day 270
Occurrence of HZ-associated any pain, persisting between 0 and 270 days after the initial visit for this study.	Day 0 - Day 270

Countries

Japan

Outcome results

None listed